Figure legends
Figure 1. An overview of study design
The cohort includes pregnant women with COVID-19 (n=19) and the healthy controls (n=28), recruited from Clinical Trials. NCT04165252 study. Longitudinal study cases were shown in purple. The three preterm birth cases were shown in black circles.
Figure 2. The comparison of alpha diversity of the vaginal microbiota between healthy controls and pregnant women with COVID-19
TC and HC refer to total COVID-19 patients (n=19) and healthy controls (n=28), respectively. Pregnant women with COVID-19 were divided into two sub-groups according to severity of disease as Asymptomatic/Mild (AMC) (n=13) and Moderate/Severe (MSC) (n=6). Mann Whitney U rank test is performed for comparison of alpha diversity metrics. Data are presented as mean The P value less than 0.05 is accepted as significant (* P<0.01, ** P<0.05). B. Beta diversity was analyzed with Bray-Curtis distances (P=0.49). Blue color refers to the healthy controls and pregnant women with COVID-19 were presented in red colour.
Figure 3. The vaginal microbiome composition of healthy controls and women with COVID-19
Healthy control (n=28) and women with COVID-19 (n=19); A. The most abundant bacteria at the phylum level are represented for two groups. B.The most abundant bacteria at the genus level are represented for two groups. C. The relative abundance of different bacteria species in two groups. Only phyla and genera present at relative abundances >0.01% are reported. Remaining taxa are grouped as “Others”.
Figure 4. The comparison of abundance of vaginal microbiota species among Healthy Controls, Asymptomatic/Mild and Moderate/Severe cases
* refers to statistical significance P<0.05; ** represents statistical significance P<0.01; P1 refers the comparison of bacteria species between the healthy controls with women with asymptomatic/mild disease; P2 refers the comparison of bacteria species between the healthy controls with women with moderate/severe disease. P3 refers to the comparison of bacteria species between women with asymptomatic/mild disease with those of moderate/severe disease.
Figure 5. The longitudinal analysis of vaginal microbiota
The abundance rate of Phyla in vaginal microbiota before COVID-19, during acute phase and after recovery in three patients (asymptomatic/mild [n=2] and moderate/severe [n=1])